Hence, the targeting of cIAP1 strongly reduces EGFR signaling with consequent inhibition of Snai2 expression, which is a well-known promoter of breast cancer cell aggressiveness (Fig. S5). This evidence concerns the gene EGFR and breast carcinoma.